Indraprastha Medical Corporation Limited (INDRAMEDCO)
₹320.05 -0.44% last close, 16 Oct
Latest quarterly results (Q1 FY27)
In its latest reported quarter, Q1 FY27, Indraprastha Medical's revenue was ₹406 Cr (+11.3% year on year, +11.3% on the previous quarter), and net profit ₹55.9 Cr (+9.5% year on year); the operating margin was 19.7%.
| Q1 FY27 (₹ Cr) | Value | YoY vs Q1 FY26 | QoQ |
|---|---|---|---|
| Revenue | ₹406 | +11.3% | +11.3% |
| Operating profit | ₹79.8 | +9.3% | +30.8% |
| Net profit | ₹55.9 | +9.5% | +33.0% |
| EPS (₹) | 6.09 | +8.6% | +33.8% |
| Operating margin | 19.7% | — | — |
INDRAMEDCO delivery percentage
NSE end-of-day data for
On Fri, 16 Oct 2026, 57.06% of the INDRAMEDCO shares traded on NSE were taken to delivery, against the stock's own 20-session average of 60.13%. That is close to its usual level. Volume was 0.4 times its average, well below normal.
Delivery in the last 5 sessions: 50.1% · 82.5% · 47.9% · 62.7% · 57.1%
A description of what the exchange published, not a recommendation. Names such as "accumulation" or "long buildup" label a pattern in the numbers. How delivery is analysed
📢 Recent Corporate Announcements
Indraprastha Medical Corporation Limited has submitted its Annual Report for FY2025-26 along with the Notice for its 38th Annual General Meeting scheduled for September 24, 2026. The company reported full-year FY26 revenue from operations of ₹1,482.51 crore, up 9.3% from ₹1,356.36 crore in FY25. The Board has declared a dividend of ₹4 per share for the financial year. Operational highlights noted an expansion to 42 robotic systems completing over 7,000 robotic-assisted surgeries during FY26.
- 38th Annual General Meeting scheduled for September 24, 2026 via Video Conferencing.
- FY26 Revenue from Operations stood at ₹1,482.51 crore compared to ₹1,356.36 crore in FY25.
- Dividend of ₹4 per share declared for FY2025-26.
- Completed 7,000+ robotic-assisted surgeries across 42 robotic systems during FY 2025-26.
Indraprastha Medical Corporation Limited has scheduled its 38th Annual General Meeting (AGM) for September 24, 2026, and fixed September 18, 2026, as the record date for a dividend of Rs 4.00 per share (40% on face value of Rs 10) for FY 2025-26. The proposed payout represents an aggregate distribution of approximately Rs 36.6 crore, which is ~39.8% of the company's TTM net profit of Rs 92 crore. At the current market price of Rs 368.1, the dividend corresponds to a yield of roughly 1.1%. Subject to shareholder approval at the AGM, the dividend will be disbursed within 30 days of declaration.
- Proposed dividend of Rs 4.00 per equity share (40% of Rs 10 face value) for FY 2025-26
- Record date and cut-off date fixed for Friday, September 18, 2026
- 38th Annual General Meeting to be held on Thursday, September 24, 2026
- Payment to be disbursed within 30 days from date of shareholder approval
Indraprastha Medical Corporation Limited has scheduled its 38th Annual General Meeting for Thursday, September 24, 2026, via Video Conferencing. The company has fixed Friday, September 18, 2026, as the Record Date for determining eligibility for a dividend of Rs 4.00 per equity share (40% on Rs 10 face value) for FY 2025-26. The cut-off date for remote e-voting is also set for September 18, 2026. Upon shareholder approval at the AGM, the dividend will be distributed within 30 days.
- Dividend recommended at Rs 4.00 per share (40% on face value of Rs 10) for FY 2025-26
- Record Date fixed as Friday, September 18, 2026, for dividend entitlement
- Cut-off date for remote e-voting set for September 18, 2026
- 38th AGM to be held on Thursday, September 24, 2026, via VC/OAVM
- Dividend to be paid within 30 days from approval date at the AGM
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported a steady Q1 FY27 with revenue from operations rising 11.2% YoY to ₹406.15 cr. Net profit (PAT) grew by 8.5% YoY to ₹55.85 cr, while Profit Before Tax (PBT) saw a 9.5% increase to ₹74.82 cr. The company has fixed September 18, 2026, as the record date for the FY26 dividend and the upcoming Annual General Meeting. Operating margins faced slight pressure as professional charges to doctors rose 13.6% YoY, outpacing revenue growth.
- Revenue from operations increased to ₹406.15 cr in Q1 FY27 from ₹365.06 cr in Q1 FY26.
- Net Profit (PAT) for the quarter stood at ₹55.85 cr, up from ₹51.46 cr in the previous year's corresponding quarter.
- Professional charges to doctors, a key expense, rose by 13.6% YoY to ₹111.15 cr.
- Basic and Diluted EPS for the quarter improved to ₹6.09 from ₹5.61 YoY.
- Record date for dividend and the 38th AGM (scheduled for Sept 24) is fixed as September 18, 2026.
Indraprastha Medical Corporation (Indraprastha Apollo Hospitals) reported a steady Q1 FY27 with revenue from operations growing 11.2% YoY to ₹406.15 cr. Net profit for the quarter increased by 8.5% to ₹55.85 cr, up from ₹51.46 cr in the year-ago period. The Board has fixed September 18, 2026, as the record date for the FY26 dividend and the upcoming 38th Annual General Meeting. Operational margins remained healthy with a Profit Before Tax (PBT) of ₹74.82 cr, representing an 18.4% margin on total income.
- Revenue from operations increased 11.2% YoY to ₹406.15 cr in Q1 FY27.
- Net Profit (PAT) rose 8.5% YoY to ₹55.85 cr for the quarter ended June 2026.
- Record date for dividend and 38th AGM fixed for September 18, 2026.
- Professional charges to doctors, a key cost component, rose 13.6% YoY to ₹111.15 cr.
- Earnings Per Share (EPS) for the quarter stood at ₹6.09 compared to ₹5.61 in Q1 FY26.
Indraprastha Medical Corporation reported a steady Q1 FY27 with revenue from operations growing 11.3% YoY to ₹406.15 cr. Net profit (PAT) increased by 8.5% YoY to ₹55.85 cr, resulting in an EPS of ₹6.09 compared to ₹5.61 in the previous year's quarter. The Board has fixed September 18, 2026, as the record date for the FY26 dividend. While revenue grew, professional charges to doctors rose 13.6% YoY to ₹111.15 cr, slightly impacting margin expansion.
- Revenue from operations increased 11.26% YoY to ₹406.15 cr in Q1 FY27.
- Profit After Tax (PAT) grew 8.53% YoY to ₹55.85 cr from ₹51.46 cr.
- Professional charges to doctors rose to ₹111.15 cr, accounting for 27.4% of total revenue.
- Record date for FY26 dividend and 38th AGM fixed for September 18, 2026.
- Total comprehensive income for the period stood at ₹58.10 cr, up from ₹55.94 cr YoY.
Indraprastha Medical Corporation Limited has filed its quarterly compliance certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018. The certificate, issued by its Registrar & Share Transfer Agent, MUFG Intime India Private Limited, confirms the processing of share certificates for the quarter ended June 30, 2026. This is a standard administrative procedure confirming that physical shares received for dematerialization were verified, cancelled, and the records updated with the depositories. There is no impact on the company's financial or operational standing.
- Compliance filing under Regulation 74(5) of SEBI (Depositories and Participants) Regulations, 2018
- Covers the three-month period ending June 30, 2026
- Certificate issued by Registrar & Share Transfer Agent, MUFG Intime India Private Limited, on July 6, 2026
- Confirms that share certificates were mutilated and cancelled after due verification
Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals) has announced the closure of its trading window starting July 1, 2026, in compliance with SEBI insider trading regulations. This closure is ahead of the un-audited financial results for the quarter ending June 30, 2026. The restriction applies to all designated persons, including promoters and directors, and will last until 48 hours after the results are declared. The date for the board meeting to approve these results is yet to be announced.
- Trading window closure effective from July 1, 2026
- Relates to un-audited financial results for the quarter ending June 30, 2026
- Window reopens 48 hours after the financial results are declared to stock exchanges
- Restriction applies to promoters, directors, and designated employees
Indraprastha Medical Corporation Limited has scheduled a series of one-on-one investor meetings in Mumbai on June 4 and 5, 2026. The management is set to engage with 12 high-profile entities, including HDFC Mutual Fund, SBI Mutual Fund, and PineBridge Investments. These meetings are part of the company's regular institutional outreach, and no unpublished price sensitive information (UPSI) is expected to be disclosed. The high volume of top-tier mutual funds and PMS houses participating suggests significant institutional interest in the hospital operator.
- Management to conduct one-on-one meetings with 12 institutional investors and PMS houses in Mumbai.
- Scheduled dates for the investor engagement are June 4, 2026, and June 5, 2026.
- Major participants include HDFC MF, SBI MF, Nippon MF, AXIS MF, and PineBridge Investments.
- The meetings are being held in compliance with Regulation 30 and 46 of SEBI (LODR) Regulations, 2015.
ICRA Limited has reaffirmed the credit ratings for Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals), maintaining a strong investment-grade profile. The long-term rating for Rs 132.50 crore in facilities is reaffirmed at [ICRA]AA with a Stable outlook, while short-term facilities of Rs 30 crore are maintained at [ICRA]A1+. The total rated amount of Rs 162.50 crore includes a significant proposed term loan of Rs 92.50 crore. This reaffirmation underscores the company's continued financial stability and creditworthiness in the healthcare sector.
- Long-term rating reaffirmed at [ICRA]AA (Stable) for Rs 132.50 crore in bank facilities.
- Short-term rating reaffirmed at [ICRA]A1+ for Rs 30.00 crore non-fund based limits.
- Total bank facilities rated by ICRA amount to Rs 162.50 crore.
- The rating includes a proposed term loan of Rs 92.50 crore for future capital requirements.
- Facilities are spread across major lenders including ICICI Bank, PNB, and HDFC Bank.
The Board of Directors of Indraprastha Medical Corporation Limited, at its meeting on May 12, 2026, has recommended a final dividend of Rs. 4 per equity share. This recommendation is subject to the approval of shareholders at the upcoming Annual General Meeting. The company also clarified that it does not qualify as a 'Large Corporate' under SEBI's specific regulatory framework. The board meeting concluded at 4:35 p.m. following a session that began at 3:00 p.m.
- Recommended a Final Dividend of Rs. 4 per equity share for the financial year.
- Board meeting held on May 12, 2026, concluded at 4:35 p.m.
- Confirmed non-applicability of 'Large Corporate' (LC) criteria per SEBI circulars.
- Dividend payout is subject to shareholder approval at the next AGM.
Indraprastha Medical Corporation Limited (Indraprastha Apollo Hospitals) has concluded its board meeting to approve financial results for the fiscal year ended March 31, 2026. The company officially declared that it does not meet the SEBI criteria for 'Large Corporate' (LC) status, which simplifies certain regulatory and borrowing disclosures. The board meeting was held on May 12, 2026, lasting approximately 95 minutes. This filing serves as the formal submission of the year-end financial performance to the stock exchanges.
- Board meeting concluded on May 12, 2026, for the approval of financial results for the period ended March 31, 2026.
- Company confirmed it does not fulfill criteria for 'Large Corporate' status under SEBI Circular SEBI/HO/DDHS/CIR/P/2018/144.
- The board meeting commenced at 3:00 p.m. and concluded at 4:35 p.m.
- The submission includes Annexures A, B, and C representing the detailed financial statements and audit reports.
Indraprastha Medical Corporation Limited (INDRAMEDCO) has announced that Mr. Vinayak Chatterjee ceased to be an Independent Director effective March 31, 2026. This change follows the completion of his second consecutive five-year term, totaling a decade of service on the board. As a result, he has also stepped down from his positions as a member and chairperson of various board committees. This is a routine transition in alignment with Indian corporate governance regulations regarding independent director tenures.
- Mr. Vinayak Chatterjee (DIN 00008933) retired as Independent Director on March 31, 2026.
- The cessation marks the end of his second 5-year term, the maximum allowed under current norms.
- He has vacated his roles as Member and Chairperson of several Board Committees.
- The transition is compliant with Regulation 30 of SEBI (LODR) Regulations, 2015.
Indraprastha Medical Corporation Limited has announced that its trading window will be closed starting April 1, 2026. This action is taken in accordance with SEBI Insider Trading regulations for the purpose of considering the audited financial results for the quarter and year ending March 31, 2026. The closure applies to all directors, designated employees, and insiders, preventing them from trading in company securities. The window will reopen 48 hours after the financial results are officially declared to the stock exchanges.
- Trading window closure begins on April 1, 2026, for Q4 and FY26 audited results.
- Restriction applies to all directors, designated employees, and their immediate relatives.
- The window will remain closed until 48 hours after the announcement of financial results.
- The specific date for the Board Meeting to approve the results will be announced in due course.
Indraprastha Medical Corporation Limited has announced the successful passing of four special resolutions via postal ballot as of March 21, 2026. Shareholders approved the re-appointment of three Independent Directors: Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli. Additionally, the appointment of Mr. Harsh Pati Singhania as an Independent Director was confirmed. These appointments ensure board continuity and adherence to corporate governance standards for the Apollo Hospitals-managed entity.
- Approval of 4 special resolutions regarding the appointment and re-appointment of Independent Directors.
- Re-appointment of Mr. Salil Singhal, Ms. Vineeta Rai, and Ms. Madhumita Ganguli confirmed by requisite majority.
- New appointment of Mr. Harsh Pati Singhania as an Independent Director approved.
- Remote e-voting process concluded on March 20, 2026, with results submitted by the Scrutinizer on March 21, 2026.
Financial Performance
Revenue Growth by Segment
Total income from operations grew to INR 1,356.36 Cr in FY25 from INR 1,244.70 Cr in FY24, representing a YoY increase of 8.97%. Revenue per patient increased by 2% to INR 202,869, while revenue per bed day grew by 5% to INR 66,064.
Geographic Revenue Split
The company faces high geographic concentration with 90-95% of its revenues derived from the National Capital Region (NCR), specifically from its two primary hospital properties.
Profitability Margins
Net Profit Ratio improved to 12% in FY25 compared to 10% in FY24, a 200 bps increase. Profit before tax rose 30.2% YoY to INR 216.32 Cr from INR 166.11 Cr.
EBITDA Margin
OPBITDA margins were reported at 14.3% in 9M FY23, improving from 13.5% in FY22. The improvement is driven by better operating metrics and a higher share of international patients and elective surgeries.
Capital Expenditure
Capital expenditure for FY25 was INR 36.33 Cr, a significant reduction from the INR 69.39 Cr spent in FY24. This includes investments in property, plant, equipment, and intangible assets like software licenses.
Credit Rating & Borrowing
The company maintains a strong liquidity position with ~INR 350 Cr in free cash and liquid balances. It remains debt-free with minimal gearing, resulting in robust debt protection indicators.
Operational Drivers
Raw Materials
Specific raw material names like medical consumables and pharmaceuticals are not individually listed, but 'rising material costs' are identified as a key performance risk. Inventory stood at a net change of INR 0.54 Cr for the year.
Key Suppliers
Not disclosed in available documents; however, the company follows a stringent buy-back policy with vendors for e-waste and old medical equipment.
Capacity Expansion
Current operations are concentrated in two properties in the NCR. While specific MT/MW metrics are not applicable, the company focused on increasing discharges to 64,423 (up 7% YoY) and out-patient volumes to 596,285 (up 7% YoY).
Raw Material Costs
Material costs are noted as a risk factor that could influence performance, though specific percentage of revenue is not explicitly broken down in the provided snippets.
Manufacturing Efficiency
Bed occupancy was reported at 69% in 9M FY23. Average length of stay (ALOS) improved (decreased) to 3.07 days in FY25 from 3.16 days in FY24, enhancing bed turnover efficiency.
Strategic Growth
Expected Growth Rate
9-12%
Growth Strategy
Growth is targeted through clinical excellence, innovation, and operational efficiency. The company is focusing on high-margin elective surgical procedures and has implemented price revisions to boost Average Revenue Per Operating Bed (ARPOB).
Products & Services
Healthcare services including Oncology, Neurology, Cardiology, Nephrology, and elective surgical procedures, alongside outpatient consultations and diagnostic services.
Brand Portfolio
Indraprastha Apollo Hospitals, backed by the parent brand Apollo Hospitals Enterprise Limited (AHEL).
New Products/Services
Expansion of elective surgical procedures and specialized clinical service lines are expected to be the primary drivers for FY26 growth.
Market Expansion
The company is focused on strengthening its market leadership within the NCR through technological upgrades and clinical innovation.
Market Share & Ranking
The company is a leading healthcare player in the NCR region, leveraging the Apollo brand's national market leadership.
Strategic Alliances
Apollo Hospitals Enterprise Limited (AHEL) and its promoters hold a 25% stake in the company, providing significant operational, financial, and managerial linkages.
External Factors
Industry Trends
The healthcare industry is seeing a shift toward elective surgeries and specialized care (Oncology/Cardiology). There is a growing trend toward energy efficiency in hospital infrastructure and digital transformation in patient records.
Competitive Landscape
Operates in a 'heightened competition' environment in the NCR with multiple private and government healthcare providers.
Competitive Moat
The company's moat is built on the 'Apollo' brand equity, a 25% strategic stake by AHEL, and a dominant clinical reputation in the NCR. This is sustainable due to high switching costs for complex surgeries and established referral networks.
Macro Economic Sensitivity
Sensitive to changes in the political or economic landscape and tax regimes. Performance is also linked to the resumption and stability of international travel for medical tourism.
Consumer Behavior
Increased demand for elective surgical procedures and high-quality sustainable healthcare services.
Geopolitical Risks
International patient flow is subject to geopolitical stability and travel regulations, as evidenced by the significant revenue jump post-travel resumption.
Regulatory & Governance
Industry Regulations
Subject to price control measures and standard compliance requirements for medical services. It maintains cost records as prescribed under Section 148(1) of the Companies Act.
Environmental Compliance
Investments made in energy-efficient HVAC, water pumps, and chillers. Stringent buy-back policies for e-waste and medical equipment are in place to manage hazardous waste.
Taxation Policy Impact
The company is regular in depositing undisputed statutory dues including Income Tax and GST. Current tax liabilities stood at zero as of March 31, 2025, compared to INR 0.58 Cr the previous year.
Legal Contingencies
The company has disclosed pending litigations in Note 30.B and 30.C of its financial statements. While specific values are not in the summary, the auditor notes these could impact the financial position.
Risk Analysis
Key Uncertainties
Asset concentration risk is high as revenue is derived from only two properties. Regulatory interventions in pricing could impact earnings by 5-10% if aggressive caps are implemented.
Geographic Concentration Risk
90-95% of revenue is concentrated in the NCR, making the company vulnerable to regional policy changes or economic downturns.
Third Party Dependencies
Dependency on Apollo Hospitals Enterprise Limited (AHEL) for brand and managerial linkages, and on specialized vendors for medical equipment maintenance.
Technology Obsolescence Risk
Rapid technological changes in medical equipment require continuous capital reinvestment to maintain clinical excellence.
Credit & Counterparty Risk
Trade receivables increased to INR 19.36 Cr in FY25, though the company maintains a strong liquidity profile to manage working capital cycles.
